Roderich Egbert Schwarz

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Niranjan Awasthi · 17 shared papers, 2011–2026 · strength 1.31
   • Paper Editor's Note: Enhancement of Nab-paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agent… DOI 10.1158/1535-7163.mct-26-0733↗
   • Paper Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical … DOI 10.1016/j.canlet.2019.05.037↗
   • Paper Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models… DOI 10.1111/jcmm.14242↗
2. Margaret A. Schwarz · 16 shared papers, 2011–2026 · strength 1.27
   • Paper Editor's Note: Enhancement of Nab-paclitaxel Antitumor Activity Through Addition of Multitargeting Antiangiogenic Agent… DOI 10.1158/1535-7163.mct-26-0733↗
   • Paper Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical … DOI 10.1016/j.canlet.2019.05.037↗
   • Paper Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models… DOI 10.1111/jcmm.14242↗
3. Rolf A. Brekken · 4 shared papers, 2011–2015 · strength 0.17
   • Paper Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. DOI 10.1016/j.canlet.2014.12.027↗
   • Paper PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic… DOI 10.1158/1535-7163.mct-12-1123↗
   • Paper Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. DOI 10.1186/1471-2407-11-15↗
4. Norbert Kuc · 1 shared paper, 2018 · strength 0.08
   • Paper Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreati… DOI 10.1016/j.bcp.2018.09.017↗
5. Katherine T. Ostapoff · 2 shared papers, 2012–2013 · strength 0.07
   • Paper PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic… DOI 10.1158/1535-7163.mct-12-1123↗
   • Paper Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pan… DOI 10.1158/1078-0432.ccr-12-0453↗
6. Amanda Kirane · 2 shared papers, 2011–2012 · strength 0.06
   • Paper Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. DOI 10.1186/1471-2407-11-15↗
   • Paper Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pan… DOI 10.1158/1078-0432.ccr-12-0453↗
7. Bercin Kutluk Cenik · 1 shared paper, 2013 · strength 0.04
   • Paper PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic… DOI 10.1158/1535-7163.mct-12-1123↗
8. Chenyue Zhang · 1 shared paper, 2013 · strength 0.04
   • Paper Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cance… DOI 10.1093/carcin/bgt227↗
9. Francis J. Burrows · 1 shared paper, 2012 · strength 0.03
   • Paper Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pan… DOI 10.1158/1078-0432.ccr-12-0453↗
10. John Henry Heinzerling · 1 shared paper, 2011 · strength 0.02
    • Paper Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancrea… DOI 10.1186/1748-717x-6-146↗
11. Jeffrey John Meyer · 1 shared paper, 2011 · strength 0.02
    • Paper Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancrea… DOI 10.1186/1748-717x-6-146↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.